Trial Profile
A clinical trial of ARMS-I to prevent airborne transmission of coronavirus in caregivers working on the frontlines of the COVID-19 pandemic (ARMS-I COVID Study)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs Cetylpyridinium (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms ARMS-I COVID
- 06 Apr 2020 New trial record
- 02 Apr 2020 According to an University Hospitals media release, the Cleveland Foundation has authorized $1 million in emergency funding to support a significant portion of this clinical trial from previously restricted health-related research grant dollars at the foundation.
- 02 Apr 2020 According to an University Hospitals media release, if the trial is successful, UH will work closely with the FDA and other relevant authorities with the goal of swiftly securing the necessary approvals to manufacture the product in quantities necessary to broadly help protect health care workers on the frontline.